<DOC>
	<DOCNO>NCT00003437</DOCNO>
	<brief_summary>RATIONALE : Hormone therapy may stop growth cancer cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining hormone therapy chemotherapy may kill cancer cell . It yet know hormone therapy chemotherapy regimen effective acute lymphoblastic leukemia . PURPOSE : Randomized phase III trial compare effectiveness different steroid therapy chemotherapy regimens treat child acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Hormone Therapy Plus Chemotherapy Treating Children With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare effect oral prednisolone vs oral dexamethasone remission rate , event-free survival , overall survival child acute lymphoblastic leukemia . - Compare effect oral mercaptopurine ( MP ) vs oral thioguanine ( TG ) remission rate , event-free survival , overall survival patient population . - Assess effect schedule concentrate tight control maintenance therapy , compensate necessary constitutional drug resistance avoid poor physician patient compliance , event-free survival patient . - Compare pharmacokinetics MP TG patient . - Collect data presence absence minimal residual disease serial bone marrow sample assess clinical importance . OUTLINE : This randomize , multicenter study . Patients randomize twice study : prednisolone v dexamethasone mercaptopurine v thioguanine . Patients initially stratify accord risk status ( standard v intermediate v high ) . Patients stratify second randomization accord gender , age ( 2 year vs 2 9 year vs 9 year ) , WBC ( 50,000/mm^3 vs 50,000/mm^3 ) , steroid allocation , early response ( slow v rapid ) . Patients verify CNS disease receive weekly intrathecal ( IT ) methotrexate 2 consecutive clear cerebrospinal fluid sample obtain . Cranial radiotherapy administer 15-21 day week 5-8 concurrently methotrexate IT appropriate regimen . Following radiotherapy , patient receive monthly methotrexate IT 1 year every 3 month end therapy . Patients testicular infiltration receive additional radiation fraction daily 12 day testes week 5-8 . Regimen A ( standard-risk patient ) - Remission induction : Patients receive assign oral steroid ( prednisolone dexamethasone ) twice day day 1-28 ; vincristine IV day 1 , 8 , 15 , 22 ; asparaginase IM three day week 9 dos begin day 4 . Patients also receive cytarabine IT day 1 methotrexate IT day 8 . - If bone marrow M3 day 15 M2 day 29 , therapy continue regimen C. Otherwise , patient continue regimen A . - Consolidation : Patients taper assign steroid day 29-35 , plus receive vincristine IV day 29 methotrexate IT day 29 , 36 , 43 , 50 . Patients also receive oral thiopurine ( mercaptopurine thioguanine ) day 29-56 . - Interim maintenance I : Patients receive assign oral steroid twice day day 57-61 85-89 plus vincristine IV day 57 85 . Patients also receive assigned oral thiopurine day 57-105 oral methotrexate day 57 , 64 , 71 , 78 , 85 , 92 , 99 , 106 . - Delayed intensification I : Patients receive oral dexamethasone twice day day 113-119 127-133 , plus vincristine IV daunorubicin IV 6 hour day 113 , 120 , 127 . Patients also receive asparaginase IM three day week 6 dos begin day 114 115 methotrexate IT day 113 . Cyclophosphamide IV 30 minute administer day 141 . Patients also receive oral thioguanine day 141-154 , cytarabine IV subcutaneously ( SC ) twice day day 142-145 149-152 , methotrexate IT day 141 148 . - Interim maintenance II : Patients receive assign oral steroid twice day day 162-166 190-194 vincristine IV day 162 190 . Patients also receive assigned oral thiopurine day 162-210 oral methotrexate day 162 , 169 , 176 , 183 , 190 , 197 , 204 , 211 . - Delayed intensification II : Patients receive oral dexamethasone day 218-224 239-245 ; vincristine IV doxorubicin IV 6 hour day 218 , 225 , 232 ; methotrexate IT day 218 . Asparaginase IM administer three day week 6 dos begin day 219 220 . Patients receive cyclophosphamide IV 30 minute day 246 , oral thioguanine day 246-259 , cytarabine IV SC day 247-250 254-257 , methotrexate IT day 246 253 . - Maintenance : Treatment give 12-week course 6 course ( girl ) 11 course ( boy ) . Patients receive assign oral steroid twice day day 1-5 , 29-33 , 57-61 course , vincristine IV day 1 , 29 , 57 course , assigned oral thiopurine daily course . Methotrexate IT administered girl day 1 course day 84 course 6 , boy receive 1 dose day 1 course 11 . Patients also receive oral methotrexate day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 course . Regimen B ( intermediate-risk patient ) - Remission induction : Patients receive assign oral steroid , vincristine , asparaginase regimen A remission induction . Patients also receive daunorubicin IV 6 hour day 1 , 8 , 15 , 22 ; cytarabine IT day 1 ; methotrexate IT day 8 . - If bone marrow M3 day 8 M2 day 29 , therapy continue regimen C. Otherwise , patient continue regimen B . - Consolidation : The assigned steroid taper day 29-35 . Patients also receive cyclophosphamide IV 30 minute day 29 43 ; cytarabine IV SC day 30-33 , 37-40 , 44-47 , 51-54 ; oral mercaptopurine day 29-56 ; methotrexate IT day 29 , 36 , 43 , 50 . - Patients M1 M2 bone marrow day 64 proceed interim maintenance I . - Interim maintenance I : Patients receive assign steroid , vincristine , assign thiopurine , oral methotrexate regimen A . Patients also receive methotrexate IT day 64 92 . - Delayed intensification I : Patients receive oral dexamethasone day 120-126 134-140 , plus vincristine IV doxorubicin IV 6 hour day 120 , 127 , 134 . Patients also receive asparaginase IM three day week 6 dos begin day 121 122 methotrexate IT day 120 . Patients receive cyclophosphamide IV 30 minute day 148 , oral thioguanine day 148-161 , cytarabine IV SC day 149-152 156-159 , methotrexate IT day 148 155 . - Interim maintenance II : Patients receive assign oral steroid twice day day 169-173 197-201 ; vincristine IV day 169 197 ; assign oral thiopurine day 169-217 ; oral methotrexate day 176 , 183 , 190 , 197 , 204 , 211 ; methotrexate IT day 169 197 . - Delayed intensification II : Patients receive oral dexamethasone day 225-231 239-245 ; vincristine IV doxorubicin IV 6 hour day 225 , 232 , 239 ; methotrexate IT day 225 . Asparaginase IM administer three day week 6 dos begin day 226 227 . Patients receive cyclophosphamide IV 30 minute day 253 , oral thioguanine day 253-266 , cytarabine IV SC day 253-256 260-263 , methotrexate IT day 253 260 . - Maintenance : Treatment administer regimen A . Regimen C ( Slow early response regimen A B OR high-risk patient ) - Remission induction patient switch regimen A : Patients continue assign oral steroid total 35 day . Patients also receive vincristine IV day 15 , 22 , 29 , daunorubicin IV 6 hour day 15 22 . Asparaginase IM administer 3 day week 6 dos . Patients receive methotrexate IT day 29 ( patient CNS disease also receive dos day 15 22 ) . - Remission induction patient switch regimen B : Patients continue assign oral steroid total 35 day . Patients also receive vincristine IV daunorubicin IV 6 hour day 8 , 15 , 22 . Asparaginase IM continue three day week 6 dos . Patients also receive methotrexate IT day 29 ( patient CNS disease also receive dos day 14 21 ) . - Consolidation : Patients receive cyclophosphamide IV 30 minute day 36 64 ; cytarabine IV SC day 37-40 , 44-47 , 65-68 , 72-75 ; oral mercaptopurine day 36-49 64-77 ; vincristine IV day 50 , 57 , 78 , 85 ; pegaspargase IM day 50 78 ; methotrexate IT day 36 , 43 , 50 , 57 . - Interim maintenance I : Patients receive vincristine IV methotrexate IV day 99 , 109 , 119 , 129 , 139 . Pegaspargase IM administer day 100 110 methotrexate IT administer day 99 129 ( patient CNS disease receive dose day 129 ) . - Patients M1 M2 bone marrow proceed delayed intensification I . - Delayed intensification I : - Reinduction : Patients receive vincristine IV doxorubicin IV 6 hour day 162 , 169 , 176 ; oral dexamethasone twice day day 162-168 176-82 ; methotrexate IT day 162 ; pegaspargase IM day 165 . - Reconsolidation : Patients receive cyclophosphamide IV 30 minute day 190 , oral thioguanine day 190-203 , cytarabine IV SC day 191-194 197-200 , vincristine IV day 204 211 , pegaspargase IM day 204 . Methotrexate IT administer day 190 197 ( patient CNS disease receive dose day 197 ) . - Interim maintenance II : Patients receive vincristine IV methotrexate IV day 218 , 228 , 238 , 248 , 258 . Pegaspargase IM administer day 219 239 . Patients also receive methotrexate IT day 218 248 ( patient CNS disease receive dose day 248 ) . - Delayed intensification II : - Reinduction : Patients receive vincristine IV doxorubicin IV 6 hour day 274 , 281 , 288 ; oral dexamethasone twice day day 274-280 288-294 ; methotrexate IT day 274 ; pegaspargase IM day 277 . - Reconsolidation : Patients receive cyclophosphamide IV 30 minute day 302 , oral thioguanine day 302-315 , cytarabine IV SC day 303-306 309-312 , vincristine IV day 316 323 . - Maintenance : Treatment administer regimen A . PROJECTED ACCRUAL : Approximately 1,800 patient accrue study within 6 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute lymphoblastic leukemia ( ALL ) No BALL ( Burkittlike , ( 8 ; 14 ) , L3 morphology , SMIg positive ) Meets criteria one follow risk group : Standard risk 1 9 year old Highest WBC le 50,000/mm^3 BCRABL negative Not hypodiploid No MLL gene rearrangement 12 24 month old Intermediate risk Over 10 year old AND/OR WBC great 50,000/mm^3 BCRABL negative Not hypodiploid No MLL gene rearrangement 12 24 month old High risk , define least 1 follow : Slow early response regimen A B BCRABL positive Hypodiploid MLL gene rearrangement 12 24 month old PATIENT CHARACTERISTICS : Age : 1 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other Previous treatment HR1 regimens allow</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2003</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
</DOC>